Benign Prostatic Hyperplasia

The presentations featured data on the drug candidate BOTRESO for BPH and LUTS, as well as on the prostate cancer prevention drug MCS-8.

"We are lucky to be in the position to offer so many treatment options customized to address [patients'] needs and help them enjoy life," says Kevin C. Zorn, MD, FRCSC, FACS.

However, M-HoLEP was superior in terms of enucleation time and efficiency, catheterization time, and hospital stay.

According to the authors, these data support Rezūm as an alternative first-line treatment option for patients at risk of BPH progression.

Here’s a look back at notable news between April and June 2025.

A recap of the FDA submissions and regulatory decisions in urology from June 2025.

The system is now cleared for use in prostates up to 150 cm3.

Amy E. Krambeck, MD, discusses how to define success and how to determine the optimal timing for adding on a new partner.

The approval is supported by several studies highlighting the efficacy of Rezūm Water Vapor Therapy in patients with larger prostates.

MIST utilization increased from 7% in 2015 to 51% in 2022 among men aged 50 to 54.

“We have definitely seen a shift in the idea of being able to really tailor treatments to both the individual and terms of what is important to them with values and preferences, as well as their individual prostate,” says Dean Elterman, MD, MSc.

Further follow-up and additional treatments in the study are ongoing.

“We're now entering an era of new types of technologies to treat BPH in a minimally invasive fashion,” says Dean Elterman, MD.

Panelist discusses how urologists can benefit from adopting newer treatment modalities like aqua ablation for BPH, emphasizing its growing popularity, ease of learning, and efficiency in improving patient throughput, while still allowing urologists to leverage their existing skills.

James C. Ulchaker, MD, shares his insights on the current range of BPH therapies.

Panelist discusses how hospitals benefit from adopting aqua ablation therapy by improving surgical efficiency, reducing turnover times, enabling outpatient procedures, and providing a highly effective treatment option that can enhance patient outcomes while preserving sexual function.

Panelist discusses how the ability to administer treatments robotically, regardless of prostate size, affects resource expenditures in a clinic, highlighting the need for extended recovery periods and increased use of apps to streamline patient management and reduce resource burdens.

Urologist Garrett D. Pohlman, MD, reflects on the benign prostatic hyperplasia offerings from the 2025 American Urological Association Annual Meeting.

Amy E. Krambeck, MD, recaps her talk from AUA 2025.

Panelist discusses how benign prostatic hyperplasia (BPH) and its treatments impact men’s sexual health, emphasizing the importance of balancing symptom relief with sexual function preservation, and how patient concerns, along with treatment advancements like aqua ablation, have simplified decision-making in clinical practice.

The investigators reported an overall incidence of AEs of 29.6%.

No device- or procedure-related serious AEs were observed through 12 months across the entire study population

Panelist discusses how clinical data from multiple studies demonstrate that aqua ablation therapy offers efficacy comparable with that of transurethral resection of the prostate (TURP) while providing superior safety, functionality, and durability benefits.

The RAPID-III trial will assess outcomes with flexible cystoscopy with or without the FloStent implant deployed.

Panelist discusses how patient outcomes have evolved over time with different benign prostatic hyperplasia (BPH) treatments, highlighting improvements in ejaculation preservation, durability, and post procedure complications across various techniques.